- Home
- ATAI vs CDLX Comparison
ATAI vs CDLX Comparison
Compare ATAI & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- CDLX
- Stock Information
- Founded
- ATAI 2018
- CDLX 2008
- Country
- ATAI Germany
- CDLX United States
- Employees
- ATAI N/A
- CDLX N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- CDLX Computer Software: Programming Data Processing
- Sector
- ATAI Health Care
- CDLX Technology
- Exchange
- ATAI Nasdaq
- CDLX Nasdaq
- Market Cap
- ATAI 222.3M
- CDLX 180.4M
- IPO Year
- ATAI 2021
- CDLX 2018
- Fundamental
- Price
- ATAI $1.50
- CDLX $3.40
- Analyst Decision
- ATAI Strong Buy
- CDLX Hold
- Analyst Count
- ATAI 4
- CDLX 6
- Target Price
- ATAI $9.00
- CDLX $5.90
- AVG Volume (30 Days)
- ATAI 1.9M
- CDLX 936.2K
- Earning Date
- ATAI 11-13-2024
- CDLX 03-13-2025
- Dividend Yield
- ATAI N/A
- CDLX N/A
- EPS Growth
- ATAI N/A
- CDLX N/A
- EPS
- ATAI N/A
- CDLX N/A
- Revenue
- ATAI $331,000.00
- CDLX $293,468,000.00
- Revenue This Year
- ATAI $80.07
- CDLX N/A
- Revenue Next Year
- ATAI N/A
- CDLX $3.49
- P/E Ratio
- ATAI N/A
- CDLX N/A
- Revenue Growth
- ATAI N/A
- CDLX N/A
- 52 Week Low
- ATAI $1.03
- CDLX $2.76
- 52 Week High
- ATAI $2.85
- CDLX $20.52
- Technical
- Relative Strength Index (RSI)
- ATAI 52.34
- CDLX 48.09
- Support Level
- ATAI $1.36
- CDLX $2.76
- Resistance Level
- ATAI $1.50
- CDLX $3.92
- Average True Range (ATR)
- ATAI 0.15
- CDLX 0.26
- MACD
- ATAI -0.00
- CDLX -0.02
- Stochastic Oscillator
- ATAI 41.43
- CDLX 54.35
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K., and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.